Comparative risk of incident and recurrent acute anterior uveitis across different biological agents in patients with ankylosing spondylitis.

IF 4.7 2区医学 Q1 RHEUMATOLOGY Rheumatology Pub Date : 2025-02-01 DOI:10.1093/rheumatology/keae003

Oh Chan Kwon, Hye Sun Lee, Juyeon Yang, Min-Chan Park

{"title":"Comparative risk of incident and recurrent acute anterior uveitis across different biological agents in patients with ankylosing spondylitis.","authors":"Oh Chan Kwon, Hye Sun Lee, Juyeon Yang, Min-Chan Park","doi":"10.1093/rheumatology/keae003","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the comparative risk of incident and recurrent acute anterior uveitis (AAU) across different biological DMARDs (bDMARDs) in patients with AS.Methods: A retrospective nationwide cohort study was conducted on 34 621 patients with AS without a previous history of AAU using a national claims database. Patients were followed-up from 2010 to 2021. The comparative risk of incident and recurrent AAU across different bDMARDs was examined using multivariable time-dependent Cox models and counting process (Anderson-Gill) models, respectively.Results: The adjusted hazard ratios (aHRs) and 95% CIs for incident AAU (bDMARDs non-exposure as reference) were: adalimumab 0.674 (0.581-0.891), etanercept 1.760 (1.540-2.012), golimumab 0.771 (0.620-0.959), infliximab 0.891 (0.741-1.071) and secukinumab 1.324 (0.794-2.209). Compared with adalimumab exposure, etanercept [aHR 2.553 (2.114-3.083)], infliximab [aHR 1.303 (1.039-1.634)] and secukinumab [aHR 2.173 (1.273-3.710)] exposures showed a higher risk of incident AAU. The aHRs and 95% CIs for recurrent AAU (bDMARDs non-exposure as reference) were: adalimumab 0.798 (0.659-0.968), etanercept 1.416 (1.185-1.693), golimumab 0.874 (0.645-1.185), infliximab 0.926 (0.729-1.177) and secukinumab 1.257 (0.670-2.359). Compared with adalimumab exposure, etanercept exposure [aHR 1.793 (1.403-2.292)] was associated with a higher risk of recurrent AAU.Conclusion: Our data suggest preference for bDMARDs in the following order: adalimumab/golimumab > infliximab > secukinumab > etanercept (for incident AAU prevention) and adalimumab > golimumab/infliximab/secukinumab > etanercept (for recurrent AAU prevention).","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"588-596"},"PeriodicalIF":4.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/rheumatology/keae003","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the comparative risk of incident and recurrent acute anterior uveitis (AAU) across different biological DMARDs (bDMARDs) in patients with AS.

Methods: A retrospective nationwide cohort study was conducted on 34 621 patients with AS without a previous history of AAU using a national claims database. Patients were followed-up from 2010 to 2021. The comparative risk of incident and recurrent AAU across different bDMARDs was examined using multivariable time-dependent Cox models and counting process (Anderson-Gill) models, respectively.

Results: The adjusted hazard ratios (aHRs) and 95% CIs for incident AAU (bDMARDs non-exposure as reference) were: adalimumab 0.674 (0.581-0.891), etanercept 1.760 (1.540-2.012), golimumab 0.771 (0.620-0.959), infliximab 0.891 (0.741-1.071) and secukinumab 1.324 (0.794-2.209). Compared with adalimumab exposure, etanercept [aHR 2.553 (2.114-3.083)], infliximab [aHR 1.303 (1.039-1.634)] and secukinumab [aHR 2.173 (1.273-3.710)] exposures showed a higher risk of incident AAU. The aHRs and 95% CIs for recurrent AAU (bDMARDs non-exposure as reference) were: adalimumab 0.798 (0.659-0.968), etanercept 1.416 (1.185-1.693), golimumab 0.874 (0.645-1.185), infliximab 0.926 (0.729-1.177) and secukinumab 1.257 (0.670-2.359). Compared with adalimumab exposure, etanercept exposure [aHR 1.793 (1.403-2.292)] was associated with a higher risk of recurrent AAU.

Conclusion: Our data suggest preference for bDMARDs in the following order: adalimumab/golimumab > infliximab > secukinumab > etanercept (for incident AAU prevention) and adalimumab > golimumab/infliximab/secukinumab > etanercept (for recurrent AAU prevention).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

强直性脊柱炎患者使用不同生物制剂发生和复发急性前葡萄膜炎的风险比较。

目的评估强直性脊柱炎（AS）患者使用不同生物疾病修饰抗风湿药（bDMARDs）后发生和复发急性前葡萄膜炎（AAU）的风险比较：利用一个全国性索赔数据库，对34 621名既往无AAU病史的强直性脊柱炎患者进行了一项全国性回顾性队列研究。从2010年到2021年对患者进行了随访。研究分别使用多变量时间依赖性Cox模型和计数过程（AG）模型对不同bDMARDs的AAU发生和复发风险进行了比较：阿达木单抗0.674（0.581-0.891）、依那西普1.760（1.540-2.012）、戈利木单抗0.771（0.620-0.959）、英夫利昔单抗0.891（0.741-1.071）和secukinumab 1.324（0.794-2.209）。与阿达木单抗暴露相比，依那西普（aHR = 2.553 [2.114-3.083]）、英夫利昔单抗（aHR = 1.303 [1.039-1.634]）和secukinumab暴露（aHR = 2.173 [1.273-3.710]）发生AAU的风险更高。复发性 AAU 的 aHRs 和 95% CIs（以未暴露于 bDMARDs 为参照）分别为：阿达木单抗 0.798 (0.659-0.968)、依那西普 1.416 (1.185-1.693)、戈利木单抗 0.874 (0.645-1.185)、英夫利昔单抗 0.926 (0.729-1.177) 和 secukinumab 1.257 (0.670-2.359)。与阿达木单抗暴露相比，依那西普（etanercept）暴露（aHR = 1.793 [1.403-2.292]）与更高的复发性AAU风险相关：我们的数据表明，按以下顺序优先选择bDMARDs：阿达木单抗/戈利木单抗>英夫利西单抗>secukinumab>依那西普（用于预防偶发性AAU），阿达木单抗>戈利木单抗/英夫利西单抗/secukinumab>依那西普（用于预防复发性AAU）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Rheumatology 医学-风湿病学

CiteScore

9.40

自引率

7.30%

发文量

1091

审稿时长

2 months

期刊介绍： Rheumatology strives to support research and discovery by publishing the highest quality original scientific papers with a focus on basic, clinical and translational research. The journal’s subject areas cover a wide range of paediatric and adult rheumatological conditions from an international perspective. It is an official journal of the British Society for Rheumatology, published by Oxford University Press. Rheumatology publishes original articles, reviews, editorials, guidelines, concise reports, meta-analyses, original case reports, clinical vignettes, letters and matters arising from published material. The journal takes pride in serving the global rheumatology community, with a focus on high societal impact in the form of podcasts, videos and extended social media presence, and utilizing metrics such as Altmetric. Keep up to date by following the journal on Twitter @RheumJnl.